Navigation Links
£3m drug safety center investment
Date:1/29/2014

LIVERPOOL, UK 29 January 2014: The Medical Research Council (MRC) Centre for Drug Safety Science at the University of Liverpool has received three million pounds of new funding from MRC to allow it to continue reducing the impact of adverse reactions to medicinal drugs.

Adverse drug reactions result in one in 15 hospital admissions and cost the NHS in excess of 650 million every year. They are also a significant cause of drug attrition for the pharmaceutical industry. The Centre addresses these problems by gaining an understanding of the fundamental mechanisms that drive adverse drug reactions to improve patient care.

The new funding will allow the Centre to consolidate its main areas of research on drug-induced liver injury and drug-induced skin hypersensitivity, for which it is internationally renowned. The funding will also enable the development of new expertise in the significant clinical problem of gastrointestinal drug toxicity.

Training is a significant part of the Centre's mission and the funding will allow it to continue to train the next generation of clinical and non-clinical drug safety scientists to bridge the skills gap in this area for pharmaceutical companies, the biotechnology sector, contract research organisations and academia.

The Centre works alongside partners from academia, regulatory authorities and industry and has attracted over 16 million in additional funding since it was set up in 2008.

Professor Kevin Park, Director of the Centre said: "This is good news for the University of Liverpool and highlights the value that the MRC sees in our national centre of excellence. It is also good news for the people who are affected by adverse reactions to medicines".

Professor Munir Pirmohamed, Head of Department of Pharmacology said: "This highlights the critical mass of expertise we have in drug safety in Liverpool. The new funding and new equipment will allow us to continue to train scientists and clinicians and translate our research into both medical practice and drug development processes. Ultimately we want to make drugs much safer for everybody."

Dr Nathan Richardson, Head of Molecular and Cellular Medicine, MRC said: "The Centre has built up an impressive bio-analytical and training facility in the first five years of core funding, with partnerships between academics, clinicians, industry and regulatory authorities.

"Positioned as a key part of MRC's portfolio in drug safety science research, we are delighted to continue strategic support for the Centre, and look forward to seeing increasing impact of its research in clinical care, including through the new research area of gastrointestinal toxicity."


'/>"/>

Contact: Jamie Brown
jamie.brown@liverpool.ac.uk
44-151-794-2248
University of Liverpool
Source:Eurekalert

Related biology news :

1. Scientists awarded £3M to study the way Northwest European seas absorb carbon
2. Aspartame passes stiff review by European Food Safety Authority
3. Safety in numbers? Not so for corals
4. Duke wins $15 million renewal to study nanotech safety
5. UH among Texas institutions that will lead Ocean Energy Safety Institute
6. Findings announced from landmark study on safety of adolescent bariatric surgery
7. Reassuring findings released in national study of influenza vaccine safety in pregnancy
8. Seafood still considered a good source of nutrients but consumers confused on safety
9. RNA-interference pesticides will need special safety testing
10. Revolutionary Face Recognition Media Exploitation System Now Available to Enhance Public Safety in Europe
11. Additional research must be done to ensure safety of pit latrines, new study says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology: